Série de bulletins techniques
Tuberculose et co-infection par le VIH | 1 - 3
Accessed November 2017
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
3rd Edition – July 2017
www.msfaccess.org
Un análisis desde la perspectiva del sector de la salud en América Latina y el Caribe
Washington, D.C., 2017
Technical Update
HIV Treatment
July 2017
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
These guidelines present evidence-based recommendations and best practice statements on use of medically important antimicrobials in food-producing animals, based on the WHO list of critically important antimicrobials for human medicine (WHO CIA List). These guidelines aim primarily to help preserve... the effectiveness of medically important antimicrobials, particularly those antimicrobials judged to be critically important to human medicine and also help preserve the effectiveness of antimicrobials for veterinary medicine, in direct support of the WHO global action plan on antimicrobial resistance
more
Doc. No.: INS/GDL/001-(Annexes)
Accessed November 2, 2017
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more